Judge Decertifies Class In Off-Label Neurontin Suit

Law360, New York (February 11, 2009, 12:00 AM EST) -- A Philadelphia judge has decertified a class in a putative action against Pfizer Inc. over off-label marketing of generic versions of its blockbuster epilepsy drug Neurontin, finding that the class members' circumstances are too varied to proceed as a class action.

Judge Mark I. Bernstein of the Court of Common Pleas for Philadelphia County ruled Monday that the lawsuit should not proceed as a class action because individual questions of fact outweigh questions common to all proposed class members.

Judge Bernstein granted preliminary certification to the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.